Literature DB >> 30713370

Comparative Study between 18F FDG-PET/CT and Whole Body MRI DWIBS in Assessment of Recurrent Breast Cancer (Prospective, Comparative, Cross-sectional Study Design).

Mahmoud Rezk1, Ibrahim Nasr2, Ismail Ali3, Heba Abdelhamed2.   

Abstract

AIM: This study aims to assess the diagnostic performance of 18F-fluorodeoxyglucose-positron emission tomography/computerized tomography (18FDG-PET/CT) compared to whole body (WB) magnetic resonance diffusion-weighted imaging (DWI) with background body signal suppression (MR/DWIBS) in lesions detection in patients with recurrent breast cancer.
MATERIALS AND METHODS: Twenty-three female patients with suspected breast cancer recurrence by clinical, laboratory, or conventional imaging underwent both 18FDG-PET/CT and WB MR/DWIBS. WB 18FDG-PET/CT was performed using the standard technique. WB MR/DWIBS acquired sequences were WB DWI with short tau inversion recovery (STIR), coronal T1, and coronal STIR. Both 18FDG-PET/CT and WB-magnetic resonance imaging/DWIBS were independently interpreted using visual qualitative and quantitative analysis. Pathological findings and combined clinical/radiological follow-up data were used as a reference standard. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and overall accuracy were calculated for both techniques.
RESULTS: PET/CT demonstrated higher specificity and sensitivity indices than MR/DWIBS in the detection of the nodal and distant lesions, while the latter displayed higher sensitivity in the detection of local breast lesions. The overall sensitivity, specificity, NPV, PPV, and accuracy of PET/CT were 84.8%, 86.3%, 90.4%, 78.7%, and 85.4% versus 82.1%, 78.0%, 85.2%, 74.0%, and 80.5% for MR/DWIBS. A high degree of agreement existed between PET/CT and MR-DWIBS.
CONCLUSION: 18FDG-PET/CT is more sensitive and has superiority in the assessment of nodal and distant lesions than DWIBS that has a potential superior role in the assessment of local breast lesions. DWIBS has a promising and helpful complementary tool for 18FDG-PET/CT in the evaluation of patients with proven malignancies.

Entities:  

Keywords:  18Fluorodeoxyglucose-positron emission tomography/computerized tomographyxs; breast cancer; whole body magnetic resonance imaging-diffusion weighted imaging with background body signal suppression

Year:  2019        PMID: 30713370      PMCID: PMC6352640          DOI: 10.4103/ijnm.IJNM_121_18

Source DB:  PubMed          Journal:  Indian J Nucl Med        ISSN: 0974-0244


  14 in total

1.  Diffusion weighted imaging in breast MRI: comparison of two different pulse sequences.

Authors:  Evelyn Wenkel; Christian Geppert; Ruediger Schulz-Wendtland; Michael Uder; Berthold Kiefer; Werner Bautz; Rolf Janka
Journal:  Acad Radiol       Date:  2007-09       Impact factor: 3.173

2.  Diffusion weighted imaging with background body signal suppression / T2 image fusion in magnetic resonance mammography for breast cancer diagnosis.

Authors:  I A Nechifor-Boilă; S Bancu; M Buruian; M Charlot; M Decaussin-Petrucci; J-S Krauth; A C Nechifor-Boilă; A Borda
Journal:  Chirurgia (Bucur)       Date:  2013 Mar-Apr

3.  Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.

Authors:  Jing Gu; Tao Chan; Jingbo Zhang; Anskar Y H Leung; Yok-Lam Kwong; Pek-Lan Khong
Journal:  AJR Am J Roentgenol       Date:  2011-09       Impact factor: 3.959

Review 4.  Whole-body diffusion-weighted imaging for staging malignant lymphoma in children.

Authors:  Thomas C Kwee; Taro Takahara; Malou A Vermoolen; Marc B Bierings; Willem P Mali; Rutger A J Nievelstein
Journal:  Pediatr Radiol       Date:  2010-07-30

5.  Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.

Authors:  Daisuke Takenaka; Yoshiharu Ohno; Keiko Matsumoto; Nobukazu Aoyama; Yumiko Onishi; Hisanobu Koyama; Munenobu Nogami; Takeshi Yoshikawa; Sumiaki Matsumoto; Kazuro Sugimura
Journal:  J Magn Reson Imaging       Date:  2009-08       Impact factor: 4.813

Review 6.  Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology.

Authors:  Thomas C Kwee; Taro Takahara; Reiji Ochiai; Rutger A J Nievelstein; Peter R Luijten
Journal:  Eur Radiol       Date:  2008-04-30       Impact factor: 5.315

7.  Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display.

Authors:  Taro Takahara; Yutaka Imai; Tomohiro Yamashita; Seiei Yasuda; Seiji Nasu; Marc Van Cauteren
Journal:  Radiat Med       Date:  2004 Jul-Aug

8.  Diffusion-weighted MR imaging with background body signal suppression (DWIBS) for the diagnosis of malignant and benign breast lesions.

Authors:  Andreas Stadlbauer; Reinhard Bernt; Stephan Gruber; Wolfgang Bogner; Katja Pinker; Wilma van der Riet; Jörg Haller; Erich Salomonowitz
Journal:  Eur Radiol       Date:  2009-05-05       Impact factor: 5.315

9.  Body diffusion-weighted MR imaging using high b-value for malignant tumor screening: usefulness and necessity of referring to T2-weighted images and creating fusion images.

Authors:  Yoshito Tsushima; Akie Takano; Ayako Taketomi-Takahashi; Keigo Endo
Journal:  Acad Radiol       Date:  2007-06       Impact factor: 3.173

10.  Detection of bone metastases using diffusion weighted magnetic resonance imaging: comparison with (11)C-methionine PET and bone scintigraphy.

Authors:  Behnaz Goudarzi; Riwa Kishimoto; Shuhei Komatsu; Hiroyuki Ishikawa; Kyosan Yoshikawa; Susumu Kandatsu; Takayuki Obata
Journal:  Magn Reson Imaging       Date:  2010-01-27       Impact factor: 2.546

View more
  1 in total

1.  Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients.

Authors:  Cornelis Maarten de Mooij; Inés Sunen; Cristina Mitea; Ulrich C Lalji; Sigrid Vanwetswinkel; Marjolein L Smidt; Thiemo J A van Nijnatten
Journal:  Nucl Med Commun       Date:  2020-10       Impact factor: 1.698

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.